CN110012661A - 普利多匹定用于治疗肌张力障碍的用途 - Google Patents

普利多匹定用于治疗肌张力障碍的用途 Download PDF

Info

Publication number
CN110012661A
CN110012661A CN201780066796.2A CN201780066796A CN110012661A CN 110012661 A CN110012661 A CN 110012661A CN 201780066796 A CN201780066796 A CN 201780066796A CN 110012661 A CN110012661 A CN 110012661A
Authority
CN
China
Prior art keywords
myodystony
dystonia
twice daily
subject
pridopidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780066796.2A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·海登
史派瑞顿·帕帕佩特罗普洛斯
尤哈-马蒂·萨福拉
伊莱·埃亚勒
贝丝·博罗夫斯基
伊戈尔·D·格拉切夫
马克·福勒斯特·戈登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prinia Medical Development Co Ltd
Original Assignee
Prinia Medical Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prinia Medical Development Co Ltd filed Critical Prinia Medical Development Co Ltd
Publication of CN110012661A publication Critical patent/CN110012661A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780066796.2A 2016-08-24 2017-08-24 普利多匹定用于治疗肌张力障碍的用途 Pending CN110012661A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US62/379,175 2016-08-24
US201662395319P 2016-09-15 2016-09-15
US62/395,319 2016-09-15
PCT/US2017/048458 WO2018039475A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating dystonias

Publications (1)

Publication Number Publication Date
CN110012661A true CN110012661A (zh) 2019-07-12

Family

ID=61246309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780066796.2A Pending CN110012661A (zh) 2016-08-24 2017-08-24 普利多匹定用于治疗肌张力障碍的用途

Country Status (12)

Country Link
US (2) US11826361B2 (enExample)
EP (1) EP3503890B1 (enExample)
JP (2) JP7278210B2 (enExample)
CN (1) CN110012661A (enExample)
AU (1) AU2017315781B2 (enExample)
BR (1) BR112019003731A2 (enExample)
CA (1) CA3035099C (enExample)
DK (1) DK3503890T3 (enExample)
ES (1) ES3009437T3 (enExample)
MX (1) MX2019002190A (enExample)
PL (1) PL3503890T3 (enExample)
WO (1) WO2018039475A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
JP2016523862A (ja) 2013-06-21 2016-08-12 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ ハンチントン病を治療するための高用量プリドピジンの使用
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
JP7603713B2 (ja) * 2020-05-04 2024-12-20 プリレニア ニューロセラピューティクス リミテッド 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療
EP4642457A1 (en) * 2022-12-27 2025-11-05 Prilenia Neurotherapeutics Ltd. Pridopidine for treating juvenile huntington's disease
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function
US20250281500A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150406A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH Hydrobromide salt of pridopidine
US20150202302A1 (en) * 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
CN105592848A (zh) * 2013-06-21 2016-05-18 梯瓦制药国际有限责任公司 高剂量普利多匹定用于治疗亨廷顿舞蹈症的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
NZ552409A (en) * 2004-06-08 2010-04-30 Nsab Af Neurosearch Sweden Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
DK1802573T3 (en) 2004-10-13 2016-12-19 Teva Pharmaceuticals Int Gmbh METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE.
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
ES2458592T3 (es) 2007-04-12 2014-05-06 IVAX International GmbH Derivados de N-óxido y/o di-N-óxido de estabilizadores/moduladores de receptores de dopamina que muestran perfiles de efectos secundarios cardiovasculares mejorados
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
KR20140075703A (ko) 2011-09-07 2014-06-19 아이백스 인터내셔널 게엠베하 프리도피딘 하이드로클로라이드의 다형 형태
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
DK3419622T3 (da) 2016-02-24 2024-06-03 Prilenia Neurotherapeutics Ltd Behandling af neurodegenerativ øjensygdom med pridopidin
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
FI3504187T3 (fi) * 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
CA3036842A1 (en) 2016-09-15 2018-03-22 Prilenia Therapeutics Development Ltd. Use of pridopidine for the treatment of anxiety and depression
DK4005570T3 (da) 2016-09-16 2024-08-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse behandling af retts syndroe
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
CN110505902B (zh) 2017-01-20 2022-11-11 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗脆性x综合征的应用
ES2938546T3 (es) 2017-08-14 2023-04-12 Prilenia Neurotherapeutics Ltd Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150406A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH Hydrobromide salt of pridopidine
CN105592848A (zh) * 2013-06-21 2016-05-18 梯瓦制药国际有限责任公司 高剂量普利多匹定用于治疗亨廷顿舞蹈症的用途
US20150202302A1 (en) * 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JODY GOLDSTEIN ET AL.: "A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington’s Disease", 《MOVEMENT DISORDERS》 *
吕雪飞等: "《现代神经疾病学》", 31 July 2016 *

Also Published As

Publication number Publication date
ES3009437T3 (en) 2025-03-26
DK3503890T3 (da) 2025-01-27
JP2019524897A (ja) 2019-09-05
JP7278327B2 (ja) 2023-05-19
US20190192496A1 (en) 2019-06-27
JP2021119189A (ja) 2021-08-12
AU2017315781A1 (en) 2019-04-11
US11826361B2 (en) 2023-11-28
EP3503890A4 (en) 2020-05-06
CA3035099A1 (en) 2018-03-01
JP7278210B2 (ja) 2023-05-19
AU2017315781B2 (en) 2021-01-28
MX2019002190A (es) 2019-09-11
WO2018039475A1 (en) 2018-03-01
US20240075021A1 (en) 2024-03-07
PL3503890T3 (pl) 2025-03-24
CA3035099C (en) 2023-01-17
WO2018039475A8 (en) 2018-10-04
BR112019003731A2 (pt) 2019-07-16
EP3503890B1 (en) 2024-12-18
EP3503890A1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
JP7278327B2 (ja) ジストニアを治療するためのプリドピジンの使用
CN109923102B (zh) 普利多匹定用于治疗功能下降的用途
KR20120000560A (ko) 아미노피리딘을 사용한 연장 요법을 위한 조성물 및 방법
US20230181548A1 (en) Use of pridopidine for treating functional decline
US20250082619A1 (en) Use of pridopidine for treating functional decline
HK40115915A (en) Use of pridopidine for treating functional decline
EA041256B1 (ru) Применение придопидина для лечения ухудшения функциональной способности
CN117651555A (zh) 用于治疗由脑性瘫痪引起的运动障碍的缬苯那嗪
HK40009736B (en) Use of pridopidine for treating functional decline
HK40009736A (en) Use of pridopidine for treating functional decline
NZ751156B2 (en) Use of pridopidine for treating functional decline
NZ791717A (en) Use of pridopidine for treating functional decline

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Herzliya

Applicant after: Prinia Neuropathy Co., Ltd.

Address before: Herzliya

Applicant before: Prinia Medical Development Co., Ltd.